Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Diclofenac Epolamine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Yaral Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the partnership, EVERSANA will support the expansion of its portfolio of pain and endocrinology products in the U.S., including Flector (diclofenac epolamine), a topical prescription therapy for acute pain due to minor strains, sprains, and contusi...
Product Name : Flector
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 22, 2023
Lead Product(s) : Diclofenac Epolamine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Yaral Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Diclofenac Epolamine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Yaral Pharma Launches Diclofenac Epolamine Topical System 1.3%
Details : Diclofenac epolamine topical system 1.3% is a prescription nonsteroidal anti-inflammatory (NSAID) medicated patch indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.
Product Name : Diclofenac Epolamine-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 01, 2023
Lead Product(s) : Diclofenac Epolamine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diclofenac Epolamine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : IBSA Institut Biochimique
Deal Size : Undisclosed
Deal Type : Acquisition
IBSA Reacquires Commercial Rights to the Flector® Brand in the US
Details : With the return of the commercial rights of Flector, a product that IBSA has developed, IBSA now offers two prescription topical drugs to treat acute pain due to minor strains, sprains, and contusions.
Product Name : Flector
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 01, 2021
Lead Product(s) : Diclofenac Epolamine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : IBSA Institut Biochimique
Deal Size : Undisclosed
Deal Type : Acquisition